Roquefort Therapeutics (ROQ) Insider Trading & Ownership GBX 4.07 +0.47 (+13.06%) As of 12:14 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsInsider Trades Roquefort Therapeutics (LON:ROQ) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage60.40%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)£102,532.26Number OfInsiders Selling(Last 3 Years)0 Get ROQ Insider Trade Alerts Want to know when executives and insiders are buying or selling Roquefort Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ROQ Insider Buying and Selling by Quarter Roquefort Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/1/2023Dr Darrin DisleyInsiderBuy269,935GBX 7£18,895.457/12/2023Stephen Paul WestInsiderBuy15,730GBX 6£943.806/26/2023Stephen Paul WestInsiderBuy144,117GBX 7£10,088.196/23/2023Trevor Ajanthan (Ajan) ReginaldInsiderBuy35,265GBX 7£2,468.559/26/2022Dr Darrin DisleyInsiderBuy515,913GBX 8£41,273.047/4/2022Stephen Paul WestInsiderBuy210,000GBX 9£18,9006/30/2022Stephen Paul WestInsiderBuy55,147GBX 9£4,963.231/19/2022Stephen Paul WestInsiderBuy50,000GBX 10£5,000 (Data available from 1/1/2013 forward) ROQ Insider Trading Activity - Frequently Asked Questions Who is on Roquefort Therapeutics's Insider Roster? The list of insiders at Roquefort Therapeutics includes Dr Darrin Disley, Stephen Paul West, and Trevor Ajanthan (Ajan) Reginald. Learn more on insiders at ROQ. What percentage of Roquefort Therapeutics stock is owned by insiders? 60.40% of Roquefort Therapeutics stock is owned by insiders. Learn more on ROQ's insider holdings. Which Roquefort Therapeutics insiders have been buying company stock? The following insiders have purchased ROQ shares in the last 24 months: Dr Darrin Disley (£18,895.45), Stephen Paul West (£11,031.99), and Trevor Ajanthan (Ajan) Reginald (£2,468.55). How much insider buying is happening at Roquefort Therapeutics? Insiders have purchased a total of 465,047 ROQ shares in the last 24 months for a total of £32,395.99 bought. Roquefort Therapeutics Key ExecutivesMr. Stephen Paul West B.Com (Age 52)CA, Executive Chairman Compensation: $152.9kMr. Trevor Ajanthan Reginald (Age 52)CEO & Executive Director Compensation: $305.8kProf. Martin J. Evans FRS (Age 83)Group Chief Scientific Officer & Executive Director Compensation: $100kDr. Emma MorrisHead of Pre-Clinical Research More Insider Trading Tools from MarketBeat Related Companies ONC Insider Trades FAB Insider Trades BVX Insider Trades IXI Insider Trades OBD Insider Trades DEST Insider Trades RENE Insider Trades OCTP Insider Trades ONT Insider Trades GNS Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (LON:ROQ) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
